UK-based Global Clinical Research Organization , ClinTec International has continued its international expansion by opening fully registered offices in China, Singapore and Thailand—consolidating its presence in the Asia Pacific region. Over the next quarter, strategic moves into South Korea, Taiwan, Malaysia, and Indonesia will also take place. The expansion has also been strengthened by the recent appointment of several regional CRAs plus Mary Pan, Director Asia Pacific who has over 12 years international experience in clinical research.
ClinTec CEO, President and Founder, Dr Buttar commented, “Since ClinTec was established in 1997, entering into the emerging markets has always proved to be a huge success for us and we expect the same from the Asia Pacific market. Several multinational companies in pharmaceutical and clinical nutrition product development are already working in partnership with ClinTec to undertake significant clinical research projects across the region.”
In the current economic climate, pharmaceutical companies are searching for new ways of working and delivering global solutions. As such, they are increasingly looking to enter new markets where revenues have not yet been fully tapped, and for partnerships with global CROs capable of facilitating world-wide multicentre clinical research needs. In the past two years, ClinTec has entered 25 new countries worldwide.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.